Filter Results:
(553)
Show Results For
- All HBS Web
(730)
- News (85)
- Research (553)
- Events (3)
- Multimedia (8)
- Faculty Publications (476)
Show Results For
- All HBS Web
(730)
- News (85)
- Research (553)
- Events (3)
- Multimedia (8)
- Faculty Publications (476)
Sort by
- May 1980 (Revised July 1980)
- Case
Germany (B): The Uncertain Stride of a Reluctant Giant
Anderson, Douglas D. "Germany (B): The Uncertain Stride of a Reluctant Giant." Harvard Business School Case 380-121, May 1980. (Revised July 1980.)
- 2022
- Book
Empires of Ideas: Creating the Modern University from Germany to America to China
By: William C. Kirby
The modern university was born in Germany. In the twentieth century, the United States leapfrogged Germany to become the global leader in higher education. Will China challenge its position in the twenty-first?
Today American institutions dominate nearly every... View Details
Today American institutions dominate nearly every... View Details
Kirby, William C. Empires of Ideas: Creating the Modern University from Germany to America to China. Cambridge, MA: Belknap Press of Harvard University Press, 2022.
- 2006
- Book
Consumer Capitalism: Politics, Product Markets, and Firm Strategy in France and Germany
By: Gunnar Trumbull
Trumbull, Gunnar. Consumer Capitalism: Politics, Product Markets, and Firm Strategy in France and Germany. Ithaca: Cornell University Press, 2006.
- April 1993
- Teaching Note
Note on Corporate Governance Systems: The United States, Japan, and Germany (TN)
By: W. Carl Kester
Teaching Note for (9-292-012). View Details
- 2003
- Chapter
Regulatory Laws and Political Culture in the United States and Germany
By: Arthur A. Daemmrich
- July 2020
- Article
Lessons from the Impact of Price Regulation on the Pricing of Anticancer Drugs in Germany
By: Victoria D. Lauenroth, Aaron S. Kesselheim, Ameet Sarpatwari and Ariel Dora Stern
Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly pronounced in the U.S., it remains largely unaddressed there. In Europe, however, different approaches to regulating drug prices have been... View Details
Keywords: Pharmaceuticals; Prescription Drug Costs; Drug Pricing; Access To Care; Cost Reduction; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Cost Management; Germany
Lauenroth, Victoria D., Aaron S. Kesselheim, Ameet Sarpatwari, and Ariel Dora Stern. "Lessons from the Impact of Price Regulation on the Pricing of Anticancer Drugs in Germany." Health Affairs 39, no. 7 (July 2020): 1185–1193.
- October 1991 (Revised December 1992)
- Background Note
Note on Corporate Governance Systems: The United States, Japan, and Germany
By: W. Carl Kester and Robert W. Lightfoot
Describes and compares the corporate governance systems commonly found in the United States, Japan, and Germany. View Details
Kester, W. Carl, and Robert W. Lightfoot. "Note on Corporate Governance Systems: The United States, Japan, and Germany." Harvard Business School Background Note 292-012, October 1991. (Revised December 1992.)
- summer 1992
- Article
Governance, Contracting, and Investment Time Horizons: A Look at Japan and Germany
By: W. C. Kester
Kester, W. C. "Governance, Contracting, and Investment Time Horizons: A Look at Japan and Germany." Continental Bank Journal of Applied Corporate Finance 5, no. 2 (summer 1992): 83–98.
- December 2000
- Article
Risk versus Risk: Tragic Choices in Drug Regulation in the United States and Germany
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Risk versus Risk: Tragic Choices in Drug Regulation in the United States and Germany." Science as Culture 9, no. 4 (December 2000): 505–534.
- Other Article
Want to See the Future of Digital Health Tools? Look to Germany
By: Ariel Dora Stern, Henrik Matthies, Julia Hagen, Jan B. Brönneke and Jörg F. Debatin
A new law will make it easier to introduce and determine the benefits of new tools. Perhaps its most important provisions are its formalization of “prescribable applications,” which include standard software, SaaS, and mobile as well as browser-based apps, and the... View Details
Keywords: Health Care and Treatment; Transformation; Internet and the Web; Technological Innovation; Germany
Stern, Ariel Dora, Henrik Matthies, Julia Hagen, Jan B. Brönneke, and Jörg F. Debatin. "Want to See the Future of Digital Health Tools? Look to Germany." Harvard Business Review (website) (December 2, 2020).
- 1994
- Article
Cross-Investments in Transnational Banking: Britain, Germany and the United States in the Twentieth Century
By: G. Jones
Keywords: Investment; Banks and Banking; Business History; Banking Industry; United Kingdom; Germany; United States
Jones, G. "Cross-Investments in Transnational Banking: Britain, Germany and the United States in the Twentieth Century." Zeitschrift für Unternehmensgeschichte 39 (1994).
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- October 2012
- Case
Germany's Green Energy Revolution
By: Noel Maurer, Elena Corsi, Emilie Billaud and Emer Moloney
Maurer, Noel, Elena Corsi, Emilie Billaud, and Emer Moloney. "Germany's Green Energy Revolution." Harvard Business School Case 713-049, October 2012.
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- August 2012
- Case
Messer Griesheim (A) (Abridged)
By: Josh Lerner, Eva Lutz and Kerry Herman
In 2001, Allianz Capital Partners and Goldman Sachs acquired a majority stake in Messer Griesheim, a European industrial gas concern held by Hoechst. The dealmakers faced several challenges, including delicate corporate governance issues due to partial family... View Details
Lerner, Josh, Eva Lutz, and Kerry Herman. "Messer Griesheim (A) (Abridged)." Harvard Business School Case 813-018, August 2012.
- April 2002
- Article
A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany." Social History of Medicine 15, no. 1 (April 2002): 137–158.
- April 1984
- Teaching Note
Founding of the European Economic Community & Germany (A): The Rebirth of an Economy, Teaching Note
By: Bruce R. Scott
- October 20, 2021
- Other Article
On the Brink of a Digital Health Care Transformation: What Germany Can Learn from the United States
By: Yoni Goldwasser, William J. Gordon, Jan B. Brönneke and Ariel D. Stern
Goldwasser, Yoni, William J. Gordon, Jan B. Brönneke, and Ariel D. Stern. "On the Brink of a Digital Health Care Transformation: What Germany Can Learn from the United States." Health Affairs Blog (October 20, 2021).